LXRX
NASDAQ · Pharmaceuticals
Lexicon Pharmaceuticals Inc
$1.72
+0.08 (+4.88%)
Financial Highlights (FY 2026)
Revenue
40.90M
Net Income
-263,791,495
Gross Margin
98.0%
Profit Margin
-644.8%
Rev Growth
+369.7%
D/E Ratio
0.69
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.0% | 55.1% | 55.1% | 55.1% |
| Operating Margin | -634.2% | 30.4% | 28.2% | 31.7% |
| Profit Margin | -644.8% | 28.4% | 29.0% | 33.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 40.90M | 68.34M | 62.90M | 66.37M |
| Gross Profit | 40.09M | 37.63M | 34.64M | 36.55M |
| Operating Income | -259,413,865 | 20.76M | 17.72M | 21.02M |
| Net Income | -263,791,495 | 19.40M | 18.23M | 21.89M |
| Gross Margin | 98.0% | 55.1% | 55.1% | 55.1% |
| Operating Margin | -634.2% | 30.4% | 28.2% | 31.7% |
| Profit Margin | -644.8% | 28.4% | 29.0% | 33.0% |
| Rev Growth | +369.7% | +10.7% | +9.3% | +0.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 138.12M | 183.67M | 161.72M | 163.58M |
| Total Equity | 200.99M | 200.03M | 220.65M | 240.93M |
| D/E Ratio | 0.69 | 0.92 | 0.73 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -242,602,238 | 29.54M | 28.34M | 30.60M |
| Free Cash Flow | — | 10.65M | 12.86M | 11.69M |